What question did this study set out to answer?

To validate 3D bioprinted patient-derived tumor models for their predictive accuracy in drug testing.

Reproducible 3D Bioprinting of Patient-Derived Tumors for Preclinical Drug Testing

View Full Paper

Ask AI

Bookmark

To validate 3D bioprinted patient-derived tumor models for their predictive accuracy in drug testing.
Dissociated patient-derived ovarian and HER2+ breast tumors were bioprinted and maintained in 3D culture.
Constructs were created using biomimetic hydrogels supplemented with ECM proteins.
Viability and structural stability were evaluated using live/dead imaging, histology, flow cytometry, and quantitative microscopy.
Drug-response assays were performed with standard chemotherapy and targeted agents.
The reproducibility of bioprinted constructs was evaluated over time.
Maintained key cellular populations and functional behaviors in 3D culture.
Found that drug responses correlated with known patient outcomes, indicating greater physiological relevance compared to 2D cultures.
Achieved structural integrity and cell viability with less than 10% variation one day post-print.
Highlighted predictive validity of bioprinted constructs for assessing preclinical efficacy.

No takes yet. Share an insight, caveat, or question.

Demonstrates that 3D bioprinting accurately predicts drug responses in patient-derived tumors, suggesting better preclinical models.

March et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark